Analytical Data
-
基因名
HBG2
- Application
-
别名
HBG2;Hemoglobin subunit gamma-2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P69892
-
表达区间
1-147aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MGSMGHFTEE DKATITSLWG KVNVEDAGGE TLGRLLVVYP WTQRFFDSFG NLSSASAIMG NPKVKAHGKK VLTSLGDAIK HLDDLKGTFA QLSELHCDKL HVDPENFKLL GNVLVTVLAI HFGKEFTPEV QASWQKMVTG VASALSSRYH
-
分子量
19 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HBG2, or hemoglobin gamma 2, is a crucial gene that encodes a subunit of fetal hemoglobin (HbF), which plays a significant role in oxygen transport during fetal development. In adults, the expression of HBG2 is typically silenced, leading to the predominance of adult hemoglobin (HbA), comprised of alpha and beta chains. However, in certain hemoglobinopathies such as sickle cell disease and beta-thalassemia, reactivation of HBG2 to increase HbF levels can ameliorate disease symptoms and improve patient outcomes. Recent advances in molecular biology and genetics have sparked interest in exploring HBG2 as a therapeutic target. Researchers are investigating innovative strategies such as gene editing, pharmacological agents, and transcriptional modulators to upregulate HBG2 expression. These efforts aim not only to enhance understanding of erythropoiesis but also to develop novel treatments for debilitating blood disorders. By elucidating the regulatory mechanisms governing HBG2 expression, scientists hope to pave the way for effective therapies that harness the power of fetal hemoglobin, providing new hope for patients suffering from these genetic diseases.
